Clinical trials: Carcinoid
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- ACTION-1 (NCT05477576)
- Testing
- RYZ101, Everolimus, Sunitinib
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- RayzeBio, Inc.
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoid Syndrome, Carcinoid
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to…
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- CAREFNDR (NCT07087054)
- Testing
- Paltusotine
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 141 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Endobronchial Carcinoid
"Bronchoscopic Argon Plasma Coagulation for Managing Endobronchial Carcinoid Lesions
A small tube will go through the respiratory tract and a non contact cauterization will be done to the inside tumor
- Trial name
- NCT06757920
- Testing
- bronchoscopic argon plasma coagulation
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Alexandria University
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Carcinoid Syndrome
Study of Panitumumab in the Treatment of Carcinoid Syndrome
The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide…
- Trial name
- NCT01172717
- Testing
- Panitumumab
- Where
- 2 sites in United States
- Sponsor
- Boston Medical Center
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendocrine, Neuroendocrine Tumor
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine…
- Conditions
- Neuroendocrine, Neuroendocrine Tumor, Neuroendocrine Cancer, Neuroendocrine Carcinoma
- Trial name
- NCT02038738
- Testing
- 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Ochsner Health System
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Carcinoid Tumors
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.
- Trial name
- SUNLAND (NCT01731925)
- Testing
- Lanreotide, Sunitinib
- Where
- 20 sites in Belgium, France
- Volunteers
- 44 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00427349
- Testing
- AMG 706, octreotide
- Where
- 112 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Adult Solid Neoplasm, Lung Carcinoid Tumor
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of trebananib and temsirolimus when given together in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Solid Neoplasm, Lung Carcinoid Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01548482
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Appendix Cancer, Appendiceal Cancer
Genetics of Appendix Cancer Study
The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.
- Conditions
- Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm
- Trial name
- GAP (NCT05734430)
- Testing
- Genetic profiling, Retrospective tissue procurement
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Andreana Holowatyj, PhD, MSCI
Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates.
- Conditions
- Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas, Gep Net
- Trial name
- RGS-GEP-NET (NCT05448157)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Neuroendocrine Tumors, Carcinoid Syndrome
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
This is a multi-centric prospective interventional study in which patients with a symptomatic GEP-NET will receive octreotide LAR every 2, 3 or 4 weeks.
- Trial name
- SCIROCCO (NCT04140409)
- Testing
- Sandostatin
- Volunteers
- 10 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Carcinoid Syndrome
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.
- Trial name
- LX1606-104 (NCT01932528)
- Testing
- 500 mg [14C]-LX1606
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Neuroendocrine Tumor, Paraganglioma
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive…
- Conditions
- Neuroendocrine Tumor, Paraganglioma, Carcinoid Tumors, Neuroblastoma
- Trial name
- DOTA-TOC (NCT02177773)
- Testing
- Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)